Imperative Care Closes Series E Financing for Up to $150M

Imperative Care Inc. has closed a Series E financing round that ultimately may net the firm up to $150 million. 
 
Led by Ally Bridge Group, existing investors D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments provided financial support to the company. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.
 
“We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy,” Imperative Care Chairman/CEO Fred Khosravi said. “This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes.”
 
“As investors in Imperative Care since the company’s Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies,”  added Ally Bridge Founder/CEO Frank Yu, who has also served as an Imperative Care board member since 2019. “We are excited to support the next stage of Imperative Care’s success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease.”
  
In addition to disclosing its latest financing round, the company also appointed Shacey Petrovic to the newly created position of board vice chair. A fairly recent addition to the board (last year) Petrovic as vice chair will focus on strategies to scale the company.

“I am excited to step into this new leadership role as Imperative Care accelerates its work to deliver impactful innovations to patients at the most tenuous moments of their lives,” Petrovic commented. “My experience serving on the Imperative Care Board has been quite inspirational as the company engineers solutions to some of the greatest challenges in medicine through medtech and digital health innovations.”
 
Petrovic also serves on the boards of Exact Sciences, Ambu A/S, and Axena Health. Previously, Petrovic served on the board and was president and CEO of Insulet Corporation, a diabetes technology company. Under her leadership, Insulet grew to serve hundreds of thousands of people with diabetes worldwide.
 
“It has been a privilege to benefit from Shacey’s business acumen and strategic mastery as we position Imperative Care for long term success and scale,” Khosravi said. “On behalf of our Board of Directors, I would like to congratulate Shacey on her appointment to vice chair as we continue to build the thrombectomy company of the future with the patient at the center.”
 
Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif.